Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Papillary Craniopharyngiomas
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.
You may not be eligible for this study if the following are true:
-
1) Prior treatment with BRAF or MEK inhibitors. 2) Evidence of active bleeding, bleeding diathesis, or hemoptysis (= ½ teaspoon of red blood) = 8 weeks prior to registration.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.